Trial reportNeuro-oncology2019
Dynamic 18F-FET PET is a powerful imaging biomarker in gadolinium-negative gliomas.
Trial report in Neuro-oncology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 46 citations in OpenAlex.
- Prediction of TERTp-mutation status in IDH-wildtype high-grade gliomas using pre-treatment dynamic [European journal of nuclear medicine and molecular imaging · 2021Trial
- Applications of artificial intelligence in nuclear medicine.Zeitschrift fur medizinische Physik · 2026Review
- Intracranial Human BT12 Glioblastoma Xenograft is [Molecular pharmaceutics · 2026Article
- Characteristics of [European journal of nuclear medicine and molecular imaging · 2026Article
- Enhanced data usability in dynamicEJNMMI physics · 2026Article
- Utilizing temporal information to assess metabolic heterogeneity: a study ofQuantitative imaging in medicine and surgery · 2025Article
- Synthesis, preclinical assessment, and first-in-human study of [European journal of nuclear medicine and molecular imaging · 2025Article
- Contribution of [Pharmaceuticals (Basel, Switzerland) · 2024Review
- Impact of improved dead time correction on the quantification accuracy of a dedicated BrainPET scanner.PloS one · 2024Article
- A framework for standardised tissue sampling and processing during resection of diffuse intracranial glioma: joint recommendations from four RANO groups.The Lancet. Oncology · 2023Review
- Advanced MR Techniques for Preoperative Glioma Characterization: Part 2.Journal of magnetic resonance imaging : JMRI · 2023Review
- Clinical applications and prospects of PET imaging in patients with IDH-mutant gliomas.Journal of neuro-oncology · 2023Review
- Article
- Combination of pre-treatment dynamic [European journal of nuclear medicine and molecular imaging · 2023Article
- Multiparametric Longitudinal Profiling of RCAS-tva-Induced PDGFB-Driven Experimental Glioma.Brain sciences · 2022Article
- Review
- Maximum 11C-methionine PET uptake as a prognostic imaging biomarker for newly diagnosed and untreated astrocytic glioma.Scientific reports · 2022Article
- Diagnostic Yield and Complication Rate of Stereotactic Biopsies in Precision Medicine of Gliomas.Frontiers in neurology · 2022Article
- Dynamic amino-acid PET in neuro-oncology: a prognostic tool becomes essential.European journal of nuclear medicine and molecular imaging · 2021Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 5 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundWe aimed to elucidate the place of dynamic O-(2-[18F]-fluoroethyl)-L-tyrosine (18F-FET) PET in prognostic models of gadolinium (Gd)-negative gliomas.
methodsIn 98 patients with Gd-negative gliomas undergoing 18F-FET PET guided biopsy, time activity curves (TACs) of each tumor were qualitatively categorized as either increasing or decreasing. Additionally, post-hoc quantitative analyses were done using minimal time-to-peak (TTPmin) measurements. Prognostic factors were obtained from multivariate hazards models. The fit of the biospecimen- and imaging-derived models was compared.
resultsA homogeneous increasing, mixed, and homogeneous decreasing TAC pattern was seen in 51, 19, and 28 tumors, respectively. Mixed TAC tumors exhibited both increasing and decreasing TACs. Corresponding adjusted 5-year survival was 85%, 47%, and 19%, respectively (P < 0.001). Qualitative and quantitative TAC measurements were highly intercorrelated (P < 0.0001). TTPmin was longest (shortest) in the homogeneous increasing (decreasing) TAC group and in between in the mixed TAC group. TTPmin was longer in isocitrate dehydrogenase (IDH)-mutant tumors (P < 0.001). Outcome was similarly precisely predicted by biospecimen- and imaging-derived models. In the biospecimen model, World Health Organization (WHO) grade (P < 0.0001) and IDH status (P < 0.001) were predictors for survival. Outcome of homogeneous increasing (homogeneous decreasing) TAC tumors was nearly identical, with both TTPmin > 25 min (TTPmin ≤ 12.5 min) tumors and IDH-mutant grade II (IDH-wildtype) gliomas. Outcome of mixed TAC tumors matched that of both intermediate TTPmin (>12.5 min and ≤25 min) and IDH-mutant, grade III gliomas. Each of the 3 prognostic clusters differed significantly from the other ones of the respective models (P < 0.001).
conclusionTAC measurements constitute a powerful biomarker independent from tumor grade and IDH status.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.